arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Celldex Therapeutics, Inc.

CLDX
$28.26 ▼ -1.68 (-5.61%) at close
Healthcare ·In Vitro & In Vivo Diagnostic Substances ·USIn Vitro & In Vivo Diagnostic Substances
18 Visible periods
27 Metrics
Peer-ranked Benchmarks
Price Chart
28
Health
Poor
Bearish
auto_awesome

Analytical Summary

Celldex Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.9B
Dividend Yield —
Revenue Growth -78.0% ↘
Op. Margin None
ROIC -54.5% ↘
FCF / Share $-3.22 ↘
Trailing P/E —
Price / Book 3.6x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

18-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.54M
↓ -78.0% —
Net Income Profit after all expenses
$-258.76M
↓ -63.9% —
Operating Margin Operating profit as % of sales
-468.4%
↓ -3295.6% —
FCF / Share Free cash flow per share
$-3.22
↓ -29.7% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
17
Cash Quality ↓
56

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 18 years · 68 quarters